The injection of antigen into the ocular anterior chamber (AC) induces the generation of splenic CD4
Introduction
The injection of antigen into the anterior chamber (AC) of the eye (intracameral injection) induces an antigen-specific immune tolerance (immune deviation) termed anterior-chamberassociated immune deviation (ACAID). ACAID is characterized by the suppression of the delayed-type hypersensitivity (DTH) response and the secretion of complement-fixing IgG antibodies and IgE (1) (2) (3) (4) (5) (6) to the antigen injected into the AC. Additionally, ACAID induces an antigen-specific suppression of T h 2-mediated pulmonary pathology (7) . The intracameral injection of antigen differs from intravenous (i.v.) or mucosal administration of antigen (8) and this form of eye-derived tolerance is mediated by at least two populations of AC-induced antigenspecific splenic regulatory cells (Tregs): an antigen-specific CD4 + population that suppresses the antigen-induced proliferation and the induction of DTH (called the afferent regulators) and an antigen-specific CD8 + population that inhibits the expression of DTH (called the efferent regulators) (1, 2,9-11). However, ACAID is independent of CD4 + CD25 + FoxP3 + Treg cells (11) .
AC-induced CD8
+ regulatory cells suppress IFN-c production in vitro (12) and in vivo T cells that effect a DTH reaction in immunized mice (1, 9, 13, 14) . Further, AC-induced CD8
+ regulatory cells are restricted by Qa-1 antigens expressed by effector T cells (13) . Since the non-classical MHC class I molecule Qa-1 is known to be expressed only on activated cells (15, 16) , AC-induced CD8
+ Treg cells specifically suppress activated T cells. Thus, it can be concluded that ACAID suppresses the induction of effector T cells and also the activity of effector T cells by distinct populations of Treg cells. That ACAID may occur in humans is suggested by the demonstration that individuals with acute retinal necrosis develop antibodies but not cell-mediated immunity to Varicella zoster (17) .
A goal of induced immune regulation is the specific modulation of the induction (or recurrence) and progression of an active autoimmune disease. Although the injection of the autoantigen interphotoreceptor retinoid binding protein (IRBP) into the AC mitigates the induction of experimental autoimmune uveitis model (18, 19) , it is not clear whether the injection of myelin antigens into the AC can mediate experimental autoimmune encephalomyelitis (EAE). In this regard, antigenpresenting cells (APCs) treated in vitro with transforming growth factor (TGF)-b2 behave as similar to APCs induced by an intracameral injection (20) (21) (22) and inhibit the induction of Myelin Basic protein (MBP)-specific EAE in C57BL/6 mice, induced by adoptive transfer of lymphocytes (23) . However, most investigations on the role of Treg cells in autoimmunity do not discriminate between the induction of an autoimmune response and the regulation of active pathogenic autoimmune immunity.
Because the injection of antigen into the AC induces different phenotypes of Treg cells, we investigated the ability of splenic Treg cells induced by an intracameral injection of MOG peptide (AC-MOG) to regulate MOG -induced EAE. Here, we show for the first time that EAE can be regulated both at the priming (initiation) phase and at the chronic (effector) phase by different AC-induced Treg cells. We show that AC-induced MOG-specific CD4
+ Treg cells suppress EAE at the priming (initiation) phase of the disease but are ineffective in restricting an ongoing disease. In contrast, CD8 + Treg cells induced by an intracameral injection of MOG restrict disease progression at the effector phase but were ineffective in suppressing EAE initiation. Our results further suggest that the inhibition of active EAE by CD8 + Treg cells requires sensitivity to TGF-b by EAE effector T cells while the CD4
+ Treg cells' suppression of the induction of EAE is independent of sensitivity to TGF-b. Thus, these results demonstrate that depending on the stage of EAE, different Treg cell phenotypes could be specifically targeted for therapy.
Methods

Animals
Female C57BL/6 (Ly5.1 and Ly5.2) mice 6-8 weeks old were purchased from Charles River Laboratories (Wilmington, MA, USA). Cbl-b À/À mice (24) are maintained at the University of Connecticut Health Center. All animals were maintained by the Center for Laboratory Animal Care at the University of Connecticut Health Center. The use of animals adhered to the Association for Research in Vision and Ophthalmology (ARVO) resolution on the use of animals in ophthalmic and vision research. All works with animals have been reviewed and approved by the University of Connecticut Health Center Animal Care Committee (ACC 2004-380).
Reagents
MOG (MEVGWYRSPFSRVVHLYRNGK) peptide was prepared by the W. M. Keck facility at Yale University, New Haven. Incomplete Freund's adjuvant (IFA) and heat-killed Mycobacterium tuberculosis H37Ra were purchased from Difco Laboratory (Detroit, MI, USA). Pertussis toxin (PTX) was purchased from List Biological Labs (Campbell, CA, USA). For flow cytometry, anti-CD45.1, anti-CD8 and anti-CD4 antibodies with appropriate isotype controls were purchased from eBiosciences (San Diego, CA, USA). CD4 and CD8 T-cell isolation kits were purchased from Miltenyi Biotec Inc. (Auburn, CA, USA).
Injection of antigen into the AC (intracameral injection)
For the induction of ACAID, antigen was injected into the AC of mice as described previously (13) . Briefly, mice were anesthetized with an intra-peritoneal injection of ketamine (75 mg kg À1 )/xylazine (15 mg kg À1 ) as described. Under a dissecting microscope, a 32-G needle attached to a cannula attached to a manually controlled Hamilton syringe (Stoelting Co., Wood Dale, IL, USA) was inserted into the AC (25) . Approximately 3 ll PBS containing 15 lg ovalbumin (OVA) or 15 lg MOG was injected into the AC. The mice recovered 15-30 min after the intracamera injection and took water and food normally. Mice receiving an intracameral injection of OVA or MOG were immunized with MOG35-55-CFA at different time points to induceEAE.
Induction of EAE
For induction of active EAE, mice were injected intra-dermally with 200 lg of emulsion containing 200 lg MOG in IFA supplemented with 500 lg of M. tuberculosis H37Ra. Mice were injected intra-peritoneally with 200 ng of PTX in 100 ll of PBS shortly after and 48 h after the first immunization. Following immunization, animals were kept under observation to score the disease. Observation was done in a blinded fashion. The clinical scale was as follows: 0 = normal, 1 = limp tail, 2 = paraparesis with a clumsy gait, 3 = hind limb paralysis, 4 = quadriplegia and 5 = death.
Preparation of splenic Treg cells (AC-CD4
+ or AC-CD8 + cells)
Seven days after intracameral injection, the AC-injected mice were euthanized, spleens recovered, diced and expressed through a 40-mm nylon mesh into PBS (pH 7.2) using the plunger of a 10-ml syringe. 
Spinal cord mononuclear cell isolation and analysis
Spinal cord mononuclear cells were derived as described previously (26) . Cells were counted and then stained with anti-CD45.1, anti-CD4 and anti-CD8 (eBioscience) and analyzed by flow cytometry.
Flow cytometry
To test the purity of isolated CD4 and CD8 cells, cell samples were washed in PBS (pH 7.2) containing 0.2% BSA and 0.1% NaN 3 (FACS buffer). Aliquots containing ;10 6 cells were incubated with 100 ll of appropriately diluted antibodies for 30 min at 4°C. Flow cytometry analysis was done using FACS Calibur (BD Biosciences) and FLOWJO (Tree Star) software.
Statistics
When comparing more than two groups, repeated measures analysis of variance was used. In all comparisons, P < 0.05 was used to determine statistical significance.
Results
Intracameral injection of MOG peptide 7 days prior to the day of immunization or 1 day after the day of immunization (Fig. 1a) . Moreover, the induction or progression of EAE was not affected by an i.v. injection of 15 lg of MOG peptide on day 0 (Fig. 1a) . The intracameral injection of MOG 35-55 peptide 8 or 10 days after disease induction restricted the progression of EAE (Fig. 1a) . In both groups receiving an intracameral, EAE was induced but did not progress after reaching an average score of 1.5 (day 8 AC) and 2 (day 10 AC). An intracameral injection of MOG peptide on day 13 p.i. did not protect the animals from EAE progression (Fig. 1a) .
To determine the antigen specificity of the effect of an intracameral injection of MOG peptide on EAE, mice received an intracameral injection of OVA on day 0 and day 8 of immunization with MOG peptide. An injection of OVA into the AC did not suppress EAE induction or progression (Fig. 1a) . Injection of a different self-antigen, Myelin Basic Protein (MBP), also did not affect EAE (data not shown).
To show the effectiveness of this treatment, we immunized mice with (MOG ) and then only those animals that had a clinical EAE score of 1 or more on day 10 p.i. received AC injections of (MOG ). Fig. 1 (b) shows only mice that had a clinical EAE score on the day they received an intracameral injection of MOG peptide (i.e. day 10). All mice in Fig. 1 (b) are therefore showing EAE scores of 1 or more on day 10, when they receive an AC injection of (MOG ). We found that there was a significant protection from EAE progression in the clinically sick mice after they received an AC injection of MOG (Fig. 1b) .
Intracameral injection of MOG 35-55 peptide into CD8
À/À mice prevents the induction but not progression of MOG induced EAE
Antigen-specific splenic CD8
+ Treg cells induced by the intracameral injection of an antigen suppress a DTH response in immunized mice (1, 2, 10, 13) . To investigate the role of CD8 + regulatory cells induced by the intracameral injection of MOG peptide, CD8
À/À mice (C57BL/6 background) were immunized with MOG peptide and received an intracameral injection of MOG 7 days prior to the day of immunization or 8 days after immunization. EAE was not induced in mice receiving an intracameral injection of MOG 35-55 peptide 7 days prior to the day of immunization. However, intracameral injection of MOG 
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À/À mice 8 days p.i. did not prevent disease progression (Fig. 2) as compared with the control wildtype (WT) mice.
Transfer of AC-induced CD8
+ regulatory cells suppresses EAE progression in the recipient but cannot prevent the induction of EAE To further clarify the role of AC-induced CD8
+ regulatory cells, we recovered MOG-AC-induced splenocytes and separated them into CD8 + and CD8 À populations. These cells were then transferred into recipient MOG peptide-immunized (EAE) mice, i.v., on day 0, day 10 or day 13 with respect to the day of immunization with MOG peptide. AC-MOG peptide-induced CD8 + cells suppressed EAE progression when transferred on 10 or 13 days postimmunization but were ineffective when transferred on day 0 (Fig. 3) . The AC-induced CD8
À splenocytes (all splenocytes except CD8
+ cells) prevented the induction of EAE if transferred on the day of immunization but did not reduce the disease score when transferred 10 or 13 days postimmunization (Fig. 3) .
The MOG-AC-induced CD8 + regulatory cells are antigen specific in their function
To determine the antigen specificity of MOG peptide-AC-induced CD8 + Treg cells, AC-OVA-induced or AC-MOGinduced CD8 + splenocytes were transferred i.v. into recipient EAE mice on day 10 post-immunization. There was no suppression of disease progression in the group that received CD8 + cells recovered from mice that received an intracameral injection of OVA (Fig. 4) , but EAE progression was restricted in the group that received CD8 + cells recovered from mice that received an intracameral injection of MOG peptide (Fig. 4) . CD8 Tregs induced by the AC injection of a different self-antigen, MBP, also did not restrict EAE (data not shown). To confirm that the AC-OVA-induced CD8 + Treg cells were functional, the AC-OVA-induced CD8 + cells suppressed an OVA-specific DTH response when injected into the footpad of OVA-immunized mice challenged with OVA (data not shown).
Transfer of AC-induced CD4 + regulatory cells effectively suppresses EAE induction in the recipient but cannot prevent the progression of EAE
CD4
+ spleen cells induced by an intracameral injection of antigen specifically suppress the initiation of a DTH response in a recipient mice when transferred i.v. but do not suppress a DTH response in immunized recipients (1, 2) . To investigate the role of AC-induced CD4 + regulatory cells, spleen cells from mice receiving an intracameral injection of MOG peptide were separated into CD4 + (enriched) and CD4
À (all splenocytes except CD4 + cells) populations and these separate populations of cells were transferred i.v. into groups of recipient EAE mice on day 0 or day 10 with respect to the day of immunization. The AC-MOG-induced CD4
+ cells suppressed the induction of EAE in the recipients when transferred on day 0 of immunization but were ineffective when transferred on day 10 p.i. (Fig. 5) . Although the AC-MOG peptide-induced CD4
À population could prevent disease progression when transferred on day 10, these cells were ineffective when injected on day 0 into recipient EAE mice (Fig. 5) .
The suppression of the induction of EAE by AC-MOG-induced CD4 + regulatory cells is antigen specific
To determine the antigen specificity of the AC-MOG-induced CD4 + Treg cells, AC-OVA-induced or AC-MOG-induced CD4 + splenocytes were transferred i.v. into recipient mice on day 0 of immunization with MOG peptide. There was no suppression of EAE induction in the group that received AC-OVA-induced CD4 + cells (Fig. 6 ), but EAE induction was restricted in the group that received AC-MOG-induced CD4 + cells (Fig. 6 ). CD4 Tregs induced by the AC injection of a different self-antigen, MBP, also did not restrict EAE (data not shown). To confirm that the AC-OVA-induced CD4 + Treg cells were functional, the AC-OVAinduced CD4
+ cells suppressed an OVA-specific DTH reaction when injected i.v. in an OVA-immunized mice before being challenged with OVA (data not shown).
The suppression of EAE progression by MOG-AC-induced CD8 + regulatory cells requires functional TGF-b signaling in effector cells
We reported previously that sensitivity to TGF-b by effector T cells is necessary for the suppression of a DTH response by CD8 + regulatory cells induced by an intracameral injection of antigen, although TGF-b sensitivity by T cells is not required for the generation of these cells (14) . Further, antibodies to TGF-b inhibit the suppression of a DTH reaction by + cells was statistically significant through the clinical course after peak symptoms (*, significant difference, P< 0.05).
Fig. 3. AC-induced CD8
+ regulatory cells can restrict EAE progression but cannot prevent the induction of EAE. Mice were immunized with MOG + on day 13 was statistically significant through the clinical course after peak symptoms (*,^, #, significant difference, P< 0.05).
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AC-induced splenic CD8
+ regulatory cells (14) . Because AC-induced splenic CD8
+ regulatory cells can restrict the progression of EAE and not the induction of the disease (Figs 2-4 (Fig. 7) although the transfer of AC-MOG-induced CD8
+ spleen cells suppressed EAE in the WT mice (Fig. 7) . EAE mice significantly prevented disease development in a similar fashion as in the wild-type C57/B6 mice (Fig. 8) . In the same experiment, an intracameral injection of MOG peptide on day À7 or day 0 of immunization with MOG peptide restricted EAE induction in Cbl-b À/À as well as wildtype C57/B6 mice (data not shown).
ACAID-CD4
+ and CD8 + splenocytes migrate to the central nervous system
Because the transfer of AC-induced CD4
+ and CD8 + Tregs could suppress EAE at different stages (Figs 3 and 5) , we explored the migration of these CD4
+ and CD8 + Tregs recovered from mice that received an intracameral injection of MOG to the central nervous system (CNS). Spleen cells from mice (CD 45.1) receiving an intracameral injection of MOG peptide were transferred i.v. into congenic MOG peptide-immunized recipient mice (CD45.2), 10 days post-immunization (at disease onset). Twenty-Four hours after transfer, ;10% of the total mononuclear cells in the spinal cord consisted of splenocytes from donor mice (CD45.1) that received AC-MOG (Fig. 9a and b) . Splenocytes from donors, which did not receive any AC injection or received a non-specific antigen (OVA), failed to reach the spinal cord in significant quantity ( Fig. 9a and b) . Because naive mice (non-immunized/non-EAE) have an intact bloodbrain barrier (BBB), ACAID splenocytes were not detected in naive spinal cords after transfer ( Fig. 9a and b) . We next investigated the cellularity of the migrating donor splenocytes in the spinal cord. Splenocytes from mice receiving AC-MOG, which migrated to the spinal cord, exhibited a significant increase in CD4 + and CD8 + subsets compared with splenocytes from non-AC or OVA-AC mice that were detected in the spinal cord (Fig. 9c) . In all cases, actual cell numbers correlated with the percentages.
Discussion
Antigen injected into the AC of the eye exerts a profound and unique suppression of cell-mediated immune responses to the AC-injected antigen in the periphery (2, 10, 32) . The injection of antigen into the AC generates + cells (2 3 10 6 cells per mouse) on day 10 p.i. The control groups were given PBS. EAE scores monitored by clinical symptoms (as discussed in Fig. 1) were assessed each day. Data are presented as mean clinical scores of eight mice per group 6 standard error. Error bars are not shown for some groups to maintain clarity of figure. The differences between the control groups and Cbl-b À/À groups were not significant (*, significant difference from WT control, P < 0.05). 
and CD8
+ regulatory cells suppress different phases of a DTH response has been shown by us and others before (1, 2, 9-12). However, the suppression of the induction of an autoimmune response versus the progression of autoimmunity has not yet been clearly dissected. Because an intracameral injection of an antigen induces two different phenotypes of Treg cells, with distinct effector functions, we investigated if AC-MOG-induced splenic regulatory cells can modulate MOG-induced EAE.
To explore how MOG-induced ACAID can modulate MOG-induced EAE, different groups of EAE mice received an intracameral injection of MOG at different time points during EAE. Intracameral injection of MOG suppressed both the induction (when given on days À7 or 1 with respect to the day of MOG immunization) and the progression (when given during the late/chronic phase of EAE) of MOG-induced EAE. In fact, an intracameral injection of MOG significantly restricted disease progression in clinically sick mice.
AC-induced MOG-specific splenic CD4 + and CD8 + cells have different abilities to suppress either the induction (priming) or the progression of an autoimmune disease (EAE) induced by MOG immunization, respectively.
AC-MOG-induced regulatory CD4
+ splenic T cells suppressed EAE only when transferred on the day of immunization or within 2 days post-immunization but were ineffective at the late phase (effector/chronic phase) of EAE (days 8-13 p.i.). On the contrary, AC-induced splenic CD8 + T cells restricted active autoimmune disease and protected the mice from neurological symptoms, when transferred around days 8-10 p.i. only but were ineffective when transferred at the early time points (days 0, 1, 2). These CD8
+ Tregs injected at the time of immunization may not suppress activated effector T cells 10 days p.i. even if present because we have observed that CD8 + Tregs are no longer effective at suppressing DTH in immunized CD4 or CD8 Tregs suppress EAE at different phases 125 mice 3 days after in vivo transfer of these CD8 + Tregs (REC and Vella, A unpublished observation). This may be due to a loss of suppressive activity and/or the production of IFNc required for suppression (25) . The basis for loss in suppressive activity is under investigation. Therefore, CD8 + Tregs can only suppress the chronic/progressive phase of EAE and are ineffective when transferred in the early stage (day 0), unlike the AC-CD4
+ Tregs. The priming of MOG-specific effector T cells in EAE is believed to occur within the first 4-5 days post-immunization. Therefore, transfer of CD4 + cells from donors receiving intracameral MOG peptide may suppress the priming of EAE effector CD4 + T cells but are unable to suppress an already established disease because they do not suppress the activity of effector MOG-specific CD4 + T cells. This is further supported by the fact that AC-induced CD8 + T cells suppress the 'expression' of DTH, when transferred at the site of challenge, while the AC-induced CD4
+ T cells are ineffective when transferred to the same site (2, 9, 10, 13 + Tregs are highly antigen specific and their suppression may be directed toward TCR V-region epitopes (39, 41) . We and others have previously demonstrated that AC-induced CD8 + regulatory cells are restricted by a Qa-1-antigen complex and they express high levels of CD94/NKG2A (13, 42) . Therefore, Qa-1 restricted ACAID-induced CD8 + regulatory cells may only target activated T cells because Qa-1 has been shown to be expressed by activated T cells only (16, 39, 43, 44) . Accordingly, we suggest that MOG-AC-induced CD8
+ Treg cells only act on MOG-specific activated effector T cells, therefore they are ineffective in suppressing EAE at the priming phase but can restrict disease progression by directly acting on the activated effector cells. Hence, two different populations of Treg cells (CD4 + or CD8 + ) induced by an intracameral injection of autoantigen can either suppress the priming or the effector phase of an autoimmune response to that antigen.
The suppressive mechanism(s) of AC-induced CD4 + and CD8 + Tregs has not been clearly defined. AC-induced CD8 + Tregs secrete TGF-b, which could be one of their suppressive mechanism(s) (12, 25, 45) . In this regard, we showed previously that two strains of mice, Cbl-b À/À and dnTGF-bRII, in which the T cells do not respond to TGF-b functionally, based on different mechanisms, are also resistant to the suppression of the DTH reaction by CD8 + AC-SPL cells (10, 14) . These studies also showed that sensitivity to TGF-b is not an obligate requirement for the in vivo induction of ACinduced CD8 + Tregs (14) . Further, antibodies to TGF-b inhibit the suppression of DTH reaction by AC-induced splenic CD8 + regulatory cells (14) . Therefore, we investigated the role of TGF-b in ACAID-induced-CD4
+ and CD8 + splenic Treg cellmediated suppression of EAE. Since dnTGF-bRII mice do not develop robust EAE, we used the Cbl-b À/À mice for our studies. Mice deficient in Cbl-b have T cells that are CD28 independent in their activation and hyperactive in their responses (27, 28, 46) . In addition, Cbl-b À/À mice develop spontaneous autoimmunity and have increased susceptibility to elicited autoimmunity (46 (27) . Cbl-b À/À effector T cells have been shown to express normal levels of TGF-bRII, though an abnormality in Cbl-b À/À T cells in responding to TGF-b has been described previously (27) . In the present studies, we further extended these findings and demonstrate that Cbl-b Since AC-CD4 cells suppress EAE when transferred on the day of immunization, and the BBB is intact at that time point, it is presumed that AC-CD4 + T cells do not need to migrate to the CNS for their activity. While AC-CD8 cells are effective in suppressing EAE when transferred at a later time point during EAE, the BBB has already been breached. We therefore investigated whether transferred AC splenocytes migrate to the CNS (spinal cord) during EAE. Interestingly, only splenocytes from mice receiving an intracameral injection of MOG migrate to the CNS in significant numbers, as compared with splenocytes from non-AC or AC-OVA mice. This suggests that the migration of these cells induced by intracameral injection is antigen specific. Activated T cells can cross the BBB but there is no cognate antigen (OVA) in the spinal cord for AC-OVAinduced OVA-specific Tregs. Another possibility is that since these AC-OVA induced Tregs do not find their cognate antigen (OVA) in the spinal cord, even if they enter the cord, they might not remain there. If these MOG-specific Tregs migrate to the CNS by recognizing their cognate antigen (MOG), then it can be presumed that other CNS-specific antigens like MBP might also induce Tregs that would migrate to the CNS when transferred to a MOG-EAE mouse. But we did not find any remission in EAE when MBP was injected intracamerally into an EAE mouse or when AC-MBP-induced CD4 + or CD8 + Tregs were transferred i.v. into an EAE animal (data not shown). The cellularity of migrating donor splenocytes revealed a significantly higher amount of donor CD4 and CD8 cells in the spinal cord of mice receiving splenocytes from AC-MOG animals. Surprisingly, splenocytes from non-AC or AC-OVA mice that migrate into the CNS of the recipients consisted of mostly non-CD4 and non-CD8 cells. The lack of any specific marker to identify ACAID-induced Tregs limits our ability to experimentally confirm that these migrating CD4 and CD8 cells are ACAID Tregs. However, since these migrating CD4 or CD8 cells are found only in MOG-AC splenocytes supports the antigen specificity of this migration. Further, CD4 or CD8 cells from non-AC or OVA-AC mice did not reach the CNS in a MOG -immunized EAE animal, which indicates that the migrating CD4 and CD8 cells from MOG-AC mice are neither naive T cells nor any AC-induced activated T cells. This in conjunction with the fact that only activated cells migrate to the CNS (47-49) supports the possibility that these migrating donor CD4 and CD8 cells are ACAID-induced Tregs.
In aggregate, we demonstrate that ACAID can be used to suppress both the initiation and progression of an autoimmune response. We show for the first time that modulating an autoimmune disease at the priming stage or the chronic stage requires different types of Treg cells with different suppression mechanism(s). From the perspective of the hope that better immunotherapeutic regimens will eventually be developed to treat autoimmune diseases, this might be of particular significance, as we show a way to effectively ameliorate disease after it has already been expressed. We also propose that, a Treg-cell-based therapy for autoimmune diseases may be successful only if the specific population of Treg cells (CD8 + or CD4 + ) is used depending on the stage of the disease.
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